Skip to main content
. 2019 Jul 9;10(5):1595–1622. doi: 10.1007/s13300-019-0657-8

Fig. 7.

Fig. 7

Illustrative efficacy of SGLT2i treatments in the reduction of CVD risks in the context of commonly used CVD drugs